Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30664064 | 0.98 | FAAH (0.40) | FAAHTDP1L3MBTL1GPR84LMNA | |
| SCHEMBL19308338 | 0.98 | FAAH (0.40) | FAAHTDP1L3MBTL1GPR84LMNA | |
| SCHEMBL23750446 | 0.95 | FAAH (0.35) | FAAHTDP1L3MBTL1BDKRB2KCNH2 | |
| SCHEMBL13848610 | 0.87 | FAAH (0.34) | FAAHKCNH2 | |
| SCHEMBL21661962 | 0.83 | FAAH (0.40) | FAAHTDP1L3MBTL1LMNAKCNH2 | |
| SCHEMBL20442236 | 0.83 | FAAH (0.40) | FAAHTDP1L3MBTL1LMNAKCNH2 | |
| SCHEMBL22308327 | 0.81 | FAAH (0.40) | FAAHTDP1L3MBTL1LMNAKCNH2 | |
| SCHEMBL26078437 | 0.80 | FAAH (0.39) | FAAHTDP1L3MBTL1LMNAKCNH2 | |
| SCHEMBL21360381 | 0.80 | NR1I2 (0.40) | FAAHTDP1L3MBTL1LMNAKCNH2 | |
| SCHEMBL22460414 | 0.80 | TSHR (0.36) | TDP1L3MBTL1KCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | NOVITA PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-11701342-B2 | Co-therapies including a metastasis inhibitor | CORNELL UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20200352911-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | CORNELL UNIVERSITY | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | MIF, CXCL10, CCL2 | FAAH 3379/4885TDP1 2776/4885L3MBTL1 230/4885 |
| US-20200352911-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | MIF, CXCL10, CCL2 | FAAH 3379/4885TDP1 2776/4885L3MBTL1 230/4885 |
| US-11701342-B2 | Co-therapies including a metastasis inhibitor | MIF, CXCL10, CCL2 | FAAH 3379/4885TDP1 2776/4885L3MBTL1 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.